Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity by Morgan, Hayley & Hill, Peter A
BioMed  Central
C
TIONAL INTERNA
CANCER CELL
Page 1 of 10
(page number not for citation purposes)
Cancer Cell International
Open Access Primary research
Human breast cancer cell-mediated bone collagen degradation 
requires plasminogen activation and matrix metalloproteinase 
activity
Hayley Morgan and Peter A Hill*
Address: Department of Craniofacial Biology and Orthodontics, King's College London, Floor 22, Guy's Tower, Guy's Hospital, London, SE1 9RT 
UK
Email: Hayley Morgan - hayley.morgan@kcl.ac.uk; Peter A Hill* - peter.hill@kcl.ac.uk
* Corresponding author    
Abstract
Background: Breast cancer cells frequently metastasize to the skeleton and induce extensive
bone destruction. Cancer cells produce proteinases, including matrix metalloproteinases (MMPs)
and the plasminogen activator system (PAS) which promote invasion of extracellular matrices, but
whether these proteinases degrade bone matrix is unclear. To characterize the role that breast
cancer cell proteinases play in bone degradation we compared the effects of three human breast
cancer cell lines, MDA-MB-231, ZR-75-1 and MCF-7 with those of a normal breast epithelial cell
line, HME. The cell lines were cultured atop radiolabelled matrices of either mineralized or non-
mineralized bone or type I collagen, the principal organic constituent of bone.
Results: The 3 breast cancer cell lines all produced significant degradation of the 3 collagenous
extracellular matrices (ECMs) whilst the normal breast cell line was without effect. Breast cancer
cells displayed an absolute requirement for serum to dissolve collagen. Degradation of collagen was
abolished in plasminogen-depleted serum and could be restored by the addition of exogenous
plasminogen. Localization of plasmin activity to the cell surface was critical for the degradation
process as aprotinin, but not α2  antiplasmin, prevented collagen dissolution. During ECM
degradation breast cancer cell lines expressed urokinase-type plasminogen activator (u-PA) and
uPA receptor, and MMPs-1, -3, -9,-13, and -14. The normal breast epithelial cell line expressed low
levels of MMPs-1, and -3, uPA and uPA receptor. Inhibitors of both the PAS (aprotinin and PA
inhibitor-1) and MMPs (CT1166 and tisue inhibitor of metalloproteinase) blocked collagen
degradation, demonstrating the requirement of both plasminogen activation and MMP activity for
degradation. The activation of MMP-13 in human breast cancer cells was prevented by plasminogen
activator inhibitor-1 but not by tissue inhibitor of metalloproteinase-1, suggesting that plasmin
activates MMP-13 directly.
Conclusions: These data demonstrate that breast cancer cells dissolve type I collagen and that
there is an absolute requirement for plasminogen activation and MMP activity in the degradation
process.
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Background
Breast cancer is the most frequent cancer in the female
population of industrialized countries. Metastasis of
breast cancer cells to the skeleton occur in >70% of
patients with progressive disease, resulting in debilitating
symptoms such as severe bone pain, fractures, hypercal-
caemia and spinal cord or nerve compressions due to
extensive bone loss and tumour cell growth and expan-
sion. Such bone loss occurs as a result of increased bone
matrix resorption but the mechanisms by which cancer
cells mediate this increased degradation have not been
fully elucidated. Obviously, tumour expansion in bone
requires the removal of the extracellular matrix (ECM)
that is particularly abundant in bone. Cancer cells express
matrix metalloproteinases (MMPs) and the plasminogen
activator system (PAS) [1-3] and their levels of expression
increase with progression of the tumour.
The matrix metalloproteinases (MMPs) constitute a large
family of structurally related matrix degrading proteases
that have pivotal roles in development, tissue remodel-
ling, and cancer [4-6]. The gene family of MMPs includes
the interstitial collagenases (MMPs-1 and -13), gelatinase
A (MMP-2), gelatinase B (MMP-9), the stromelysins
(MMPs-3, 10 and 11) and the membrane type-matrix
metalloproteinases (MT-MMPs 14,15,16,17, 24 and 25)
[6]. The MMPs have the combined ability to degrade the
major components of the ECM including type I collagen,
the principal organic constituent of bone [4].
The PAS comprises: tissue-type plasminogen activator (t-
PA) and urokinase-type plasminogen activator (u-PA),
their inhibitors, and receptors. T-PA is thought to be more
important in fibrinolysis, due to its fibrin binding capac-
ity, whilst u-PA, especially when it is bound to its specific
cell surface receptor (u-PAR), is thought to be involved in
tissue remodelling and cell migration processes [7].
Whereas uPA alone recognizes a narrow range of sub-
strates, the enzyme can catalyze the conversion of the cir-
culating zymogen, plasminogen to plasmin. Plasmin, in
turn, is a broad- spectrum proteinase that can directly
degrade multiple ECM targets and can also cooperate with
other ECM-degrading enzymes including members of the
MMP gene family. Regulation of the PA/plasmin system is
achieved mainly via plasminogen activator inhibitor
(PAI) type-1 and type-2 and by agents that stimulate bone
resorption, e.g. parathyroid hormone (PTH) and inter-
leukin (IL)-1 [8].
To date, emphasis has focused on the ability of breast can-
cer cells to stimulate the formation and activity of osteo-
clasts, the cell primarily responsible for bone resorption
under physiological conditions. The ability of osteoclasts
to degrade bone lies in their ability to secrete protons and
specialized collagenolytic proteinases, the cysteine protei-
nases in the acidic microenvironment that underlies oste-
oclasts during bone resorption [9].
Experimental studies showing that increased expression
of MMPs and the PAS is associated with increased cellular
invasion in vivo support the idea that they play an impor-
tant role in metastasis of tumour cells [10,11]. Obviously
tumour expansion in bone necessitates the removal of the
ECM that is particularly abundant and resistant to degra-
dation. Synthetic inhibitors of MMPs have been devel-
oped and two recent reports on their use on in vivo breast
cancer metastasis to bone show promise when given as a
preventive treatment to mice [12,13]. However, the role of
MMPs and the PAS in mediating breast tumour bone col-
lagen dissolution has not been addressed.
We have therefore assessed the ability of three human
breast cancer cell lines, MDA-MB-231 (MDA-231), ZR-75-
1 and MCF-7 to degrade bone collagen in vitro using
matrix degradation assays and compared their effects with
those of a normal breast epithelial cell line, HME. We cor-
related the degradation activity of the breast cancer cells
with their expression of MMPs and the PAS and we
assessed the ability of group-selective proteinase inhibi-
tors to prevent degradation of the organic aspect of bone
by breast cancer cells.
Results
Type I collagen degradation
Bone degradation involves an initial phase of removal of
the unmineralized type I collagenous layer followed by
degradation of the mineralized matrix which also com-
prises type I collagen. The fibrillar integrity of the collagen
layer was confirmed by incubation with collagenase that
degraded the film whilst the collagen fibres were resistant
to degradation by both trypsin and plasmin (data not
shown). When the breast cancer cells (MDA-231, ZR-75-1
or MCF-7) were stimulated with TGFβ(10-10M) and cul-
tured in the presence of 10% FCS the cancer cells induced
significant degradation of type I collagen (range 70–
80%), whereas minimal degradation was observed in the
absence of serum (Fig. 1). To investigate the possible role
of the PAS in collagen breakdown by breast cancer cells,
plasminogen was depleted from FCS by lysine-Sepharose
chromatography [14]. Interestingly, the depletion of plas-
minogen from serum also completely blocked breast can-
cer cell mediated collagen dissolution, implicating the
PAS in breast cancer-mediated collagen degradation (Fig.
1). In accordance with this finding, the breast cancer cells
degraded collagen under serum-free conditions only
when supplemented by exogenous plasminogen (Fig. 1).
The TGFβ-stimulated normal breast cell line, HME cul-
tured in the presence of 10 % FCS demonstrated low type
I collagenase activity (Fig. 1).Cancer Cell International 2005, 5:1 http://www.cancerci.com/content/5/1/1
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The ability of the cancer cells to degrade the type I colla-
gen is consistent with the expression of proteolytic activ-
ity. However, the midpoint melting temperature of
reconstituted firbrillar type I collagen (47°C) is lower
than that of authentic type I collagen in tissues (55°C to
60°C) [4]. Because the proteinase resistance of type I col-
lagen can be compromised at temperatures within 10°C
of that at which the helix reversibly unfolds [4], reconsti-
tuted fibrillar collagen may provide a less resistant sub-
strate to proteolytic activity. Hence to determine whether
breast cancer cell mediated degradation of type I collagen
could be extended to a more physiological system, cancer
cells were cultured on bone matrix as described below.
Bone matrix degradation by breast cancer cells
The described sequential gene expression of differentiat-
ing osteoblasts [15] was verified in MC3T3-E1 cell cul-
tures so that non-mineralized matrix production was
prepared after collagen production had commenced but
before mineralization started. Mineralization of the matri-
ces was confirmed by von Kossa staining (not shown).
When TGFβ-stimulated breast cancer cell lines were cul-
tured as a monolayer on either non-mineralized (Fig. 2A)
or mineralized (Fig. 2B) bone matrix over a 24 h culture
period there was significant degradation of the non-min-
eralized matrix (range 65–75%; Fig. 2A) and to a lesser
extent the mineralized matrix (range 40–45%; Fig. 2B)
only in the presence of plasminogen. In contrast, the
TGFβ-stimulated breast cancer cell lines achieved a mini-
mal amount of degradation of either matrix in the absence
of plasminogen (Fig. 2A and 2B). The normal breast cell
line, HME achieved a minimal amount of degradation of
both matrices (5–15%) in the presence of plasminogen.
Expression of mRNA for MMPs and the PAS by breast 
tumour cells
To characterize the profile of MMPs expressed constitu-
tively and upon stimulation with TGFβ, breast cancer cells
were cultured on type I collagen. Total RNA was isolated
from 24-h cultures and screened by reverse transcription-
PCR for MMP-1 through MMP-17. Under these condi-
tions, four secreted MMPs were identified: MMP-1, MMP-
3, MMP-9, and MMP-13 and the membrane-anchored
MMP, MT1-MMP in all 3 breast cancer cell lines (Fig 3A;
MDA-231 cells shown, results similar in all 3 breast cancer
cell lines). TGFβ upregulated MMP expression in all 3 can-
cer cells lines (Fig. 3B; MDA-231 cells shown, results sim-
ilar in all 3 breast cancer cell lines). The normal epithelial
cell line, HME was found to express low levels of MMP-1
and MMP-3 upon stimulation with TGFβ (Fig. 3C)
All 3 breast cancer cell lines expressed u-PA and u-PAR
(Fig. 4A; ZR-75-1 cells shown, results similar with all 3
breast cancer cell lines) and upon stimulation with TGFβ
there was increased expression of both u-PA and u-PAR by
the breast cancer cells (Fig. 4B; ZR-75-1 cells shown,
results similar with all 3 breast cancer cell lines.). The
intensity of the signal was greater for the breast cancer
cells than the normal breast cell line, HME (Fig. 4C).
MMP and uPA production by breast cancer cells
To analyze the functional activities of MMPs and PAs
expressed in breast cancer cells, collagenase activity in
BCCM was measured by the degradation of FITC labelled
type I collagen in the presence and absence of plasmino-
gen. TGFβ markedly stimulated collagenase activity only
in the presence of plasminogen (Fig. 5). uPA production
was high in all cancer cells which degraded bone matrix
Degradation of 14C-labelled type I collagen films by breast  cancer cells Figure 1
Degradation of 14C-labelled type I collagen films by 
breast cancer cells. Breast cancer cells (105 cells/well) 
stimulated with TGFβ (10-10 M) were cultured for 24 h on 
14C-labelled type I collagen under the following conditions: 
serum-free conditions; presence of 10% serum; 10% plas-
minogen (Plg)-depleted serum; serum-free medium supple-
mented with 2 µg/ml of human Plg. After 24-h incubation, 
collagen degradation was measured as described in Materials 
and methods. 8–800 mU (Ploug units) of pure human uPA in 
1 ml of serum-free medium with or without 2 ug/ml of plas-
minogen, incubated as a control in parallel wells in the 
absence of cells, released 2–4% of the total radioactivity. This 
experiment was repeated twice. The results are expressed as 
percentage release of 14C. Each bar is the mean ± S.E.M of six 
wells. The stimulatory effects of plasminogen and TGFβ on 
breast cancer cell mediated 14C release were statistically sig-
nificant ***P < 0.001 compared with the unstimulated con-
trols and the HME cells.
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Degradation of 3H-non-mineralized (A) and 3H-mineralized (B) bone matrix by breast cancer cells Figure 2
Degradation of 3H-non-mineralized (A) and 3H-mineralized (B) bone matrix by breast cancer cells. Breast can-
cer cells (105 cells/well) stimulated with TGFβ (10-10 M) were cultured for 24 h on 3H-labelled extracellular matrices in the 
presence (+) and absence (-) of 2 µg/ml of human plasminogen. After 24-h incubation, bone matrix degradation was measured 
as described in Materials and methods. 8–800 mU (Ploug units) of pure human uPA in 1 ml of serum-free medium with or with-
out 2 µg/ml of plasminogen, incubated as a control in parallel wells in the absence of cells, released 3–4% of the total radioac-
tivity. This experiment was repeated twice. The results are expressed as percentage release of 3H labelled bone matrix. Each 
bar is the mean ± S.E.M. of six wells. The stimulatory effects of TGFβ on breast cancer cell mediated 3H release were statisti-
cally significant ***P < 0.001 compared with the unstimulated controls and the HME cells.
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but not in HME cells (Table 1) that did not degrade bone
at all, suggesting that uPA may be necessary to accomplish
this task.
Roles of MMPs and PAS in breast cancer cell mediated 
bone degradation
We examined the effects of inhibitors of MMPs and the
PAS on TGFβ-stimulated MDA-231 cell-mediated degra-
RT-PCR of MMPs in breast cancer cells Figure 3
RT-PCR of MMPs in breast cancer cells. Breast cancer 
cells were cultured as described in the Material and methods 
in the absence (A) and presence (B) of TGFβ (10-10 M). Total 
RNA was isolated and RT-PCR performed with specific prim-
ers for MMPs-1,2,3,7,8,9,10,11,12,13,14,15,16,17. The house-
keeping gene GAPDH was used as a positive control. 
Representative results for MDA-231 cells are shown (A) and 
(B): Lane 1 MMP-1; lane 2 MMP-13; lane 3 MMP-3; lane 4 
MMP-9; lane 5 MMP-14; lane 6 GAPDH. The normal breast 
cell line HME stimulated with TGFβ is shown in (C). Band 
intensities were quantified by scanning densitometry and data 
expressed as a ratio (MMP/G3PDH) of the average optical 
density (OD) × area. The ratio of the intensity of the MMP 
mRNA band over the intensity of the G3PDH mRNA was 
arbitrarily designated as 1.0. RT-PCR of uPA and uPAR in breast cancer cells Figure 4
RT-PCR of uPA and uPAR in breast cancer cells. ZR-
75-1 breast cancer cells were cultured as described in the 
material and methods in the absence (A) and presence (B) of 
TGFβ (10-10 M). Total RNA was isolated and RT-PCR per-
formed with specific primers for uPA, tPA and uPAR. The 
housekeeping gene GAPDH was used as a positive control. 
Lane 1 uPA; lane 2 uPAR; lane 3 GAPDH. The normal breast 
cell line HME stimulated with TGFβ is shown in (C). Band 
intensities were quantified by scanning densitometry and data 
expressed as a ratio (uPA or uPAR/G3PDH) of the average 
optical density (OD) × area. The ratio of the intensity of the 
uPA or uPAR mRNA band over the intensity of the G3PDH 
mRNA was arbitrarily designated as 1.0.Cancer Cell International 2005, 5:1 http://www.cancerci.com/content/5/1/1
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dation of non-mineralized bone matrix under serum free
conditions supplemented with plasminogen. The MMP
inhibitors, CT1166 and TIMP-1 completely prevented
TGFβ-stimulated breast cancer cell mediated bone colla-
gen degradation (Fig. 6). When aprotinin, which inhibits
both plasmin bound to the cell surface and plasmin in
solution, was added, collagen degradation was also com-
pletely blocked (Fig. 6). Similar inhibitory effects were
seen with function blocking antibodies to uPA or PAI-1
(Fig. 6). In contrast, the serpin α2-antiplasmin, which is a
poor inhibitor of cell surface bound plasmin but an excel-
lent inhibitor of plasmin in solution, did not prevent col-
lagen degradation (Fig. 6). Since in the absence of cells,
plasmin had no collagenolytic activity (see legend to Fig-
ures 1 and 2) and none of these inhibitors was cytotoxic,
(data not shown), these results showed that bone collagen
degradation by human breast cancer cells is dependent
upon plasminogen activation and MMP activity. Western
blot analysis demonstrated that neither CT1166 nor apro-
Collagenase activity in breast cancer conditioned media Figure 5
Collagenase activity in breast cancer conditioned 
media Breast cancer cells were cultured for 24 h in serum-
free medium in the presence and absence of 2 µg/ml of 
human plasminogen and TGFβ (10-10 M). Conditioned media 
were collected and incubated for 4 h with FITC-labelled type 
I collagen to detect collagenase activity, as described in Mate-
rial and methods. The data are expressed as means SEM of 
4–6 independent experiments, significantly different from 
control (**, P < 0.01; *** P < 0.001).
Table 1: Production of uPA by Breast Cancer Cells
Cells uPA (U/1 × 105 cells/24 h)
MDA-231 2.3
ZR-75-1 1.9
MCF-7 1.6
HME Undetected
uPA was measured by a chromogenic assay (see Materials and 
methods) in serum-free conditioned medium collected over a 24 h 
period. Breast cells were cultured in the presence of plasminogen (2 
ug/ml) and TGFβ (10-10 M). uPA was not detected in unstimulated 
breast cancer cells.
Effects of MMP and PAS inhibitors on MDA-231 cell medi- ated degradation of non-mineralized matrix Figure 6
Effects of MMP and PAS inhibitors on MDA-231 cell 
mediated degradation of non-mineralized matrix. 
MDA-231 breast cancer cells (105 cells/well) were cultured 
for 24 h on 3H-labelled extracellular matrices in the presence 
of 2 ug/ml of human plasminogen, TGFβ (10-10 M) with and 
without CT1166 (10-5 M), TIMP-1 (50 ug/ml), aprotinin (10-5 
M), antibodies to human uPA (50 µg/ml) or human uPAR (50 
µg/ml). After 24-h incubation, bone matrix degradation was 
measured as described in Materials and methods. This exper-
iment was repeated twice. The results are expressed as per-
centage release of degradation of 3H labelled bone matrix. 
Each bar is the mean ± S.E.M. of six wells. The effects of the 
inhibitors were statistically significant *P < 0.05;***P < 0.001.Cancer Cell International 2005, 5:1 http://www.cancerci.com/content/5/1/1
Page 7 of 10
(page number not for citation purposes)
tinin influenced the production of MMPs (Fig. 7A) or uPA
(Fig. 7B).
Discussion
The data presented in this paper clearly demonstrate that
human breast carcinoma cell lines have the capacity to
degrade the organic aspect of bone matrix in vitro, and
there is a dependency on the PA system for the cell-medi-
ated collagen degradation. Furthermore, we have shown
that plasmin associated with the cell surface is responsible
for activating the fibrillar collagenase, MMP-13.
The ECM in our experiments was produced by MC3T3-E1
mouse calvarial-derived cells. These cells display
osteoblast-like characteristics, providing a suitable model
of osteogenesis analogous to in vivo bone formation [17].
The bone nature is evident from the appearance of miner-
alization, resulting in the production of a solid sheet of
mineralized matrix. Our evidence showing that breast
cancer cells degrade bone matrix is in agreement with that
of Eilon and Mundy [18] who reported that MCF-7 cells
were capable of degrading the organic aspect of devital-
ized murine bone explants in vitro. More recently it has
been demonstrated that prostate cancer cells and
melanoma cells directly degrade mineralized bone matrix
and that the degradation was reduced by generalized inhi-
bition of MMP activity [19,20].
Whereas the induction of MMPs in TGFβ stimulated
breast cancer cells that are actively engaged in tumour
osteolysis has not been examined previously, this growth
factor has been reported to increase the expression of
MMPs-1, -3 and -9 [21]. In our study TGFβ induced a
complex MMP expression profile that included MMPs-1, -
3, -9 -13, and -14 as the principle products. Furthermore,
MMPs are able to release and activate TGFβ, a very abun-
dant bone matrix-bound factor [22].
The fact that breast cancer cells degraded the non-miner-
alized bone matrix to a greater extent than the mineralized
substrate, suggests that access of the matrix degrading
proteinases to the organic phase of the matrix may have
been restricted by the mineralized phase.
This investigation has demonstrated a significant differ-
ence in the ability of breast cancer cells and normal breast
epithelial cells to degrade the organic aspect of bone
matrix in vitro. Variations in the profile and amounts of
proteinases expressed by the different cell lines may be
responsible. Since the MMP inhibitors used in this study
(CT1166 and TIMP-1) inhibit the activities of all MMPs,
except the membrane-type MMPs in the case of TIMP-1,
we cannot identify the contribution of individual MMP
members to bone matrix degradation. However, our dem-
onstration of a direct requirement of plasmin in the acti-
vation of proMMP-13 suggests that this fibrillar
collagenase may play a prominent role in the degradative
activity of breast cancer cells. However, the possibility of
other known MMPs also being involved in plasminogen-
dependent collagenolysis by breast cancer cells cannot be
excluded. The participation of the membrane-type MMPs
such as MMP-14, -15 and -16 is improbable due to the
Immunological characterization of MMPs and uPA in Breast  Cancer Cells Figure 7
Immunological characterization of MMPs and uPA in 
Breast Cancer Cells. Breast cancer cells (105 cells/well) 
stimulated with TGFβ (10-10 M) were cultured for 24 h in 
serum-free medium in the presence of 2 µg/ml of human 
plasminogen and CT1166 and aprotinin. Western blot analy-
sis was undertaken as described in the Materials and meth-
ods section. Lane 1, MDA-231 cells; lane 2, ZR-75-1cells; lane 
3 MCF-7 cells; lane 4, HME cells. Pro- and active forms of 
collagenase-1 gelatinase-B, and stromelysin-1 and proform of 
collagenase-3 were detected (A). Pro and active forms of 
uPA are shown (B).Cancer Cell International 2005, 5:1 http://www.cancerci.com/content/5/1/1
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ability of TIMP-1 to effectively block collagen dissolution
by breast cancer cells. MMP-2 and – 8 were not expressed
in detectable amounts by breast cancer cells, as assessed
by RT-PCR. The existence of very small, but functionally
important, amounts of MMP-2 or – 8 however cannot be
excluded unequivocally by the expression studies. MMP-1
is expressed by the human breast cancer cells in this study
and may contribute to plasmin-dependent fibrillar colla-
gen dissolution.
Currently, little is known with regard to the physiological
mechanisms by which MMPs undergo activation in intact
cell systems [23]. However, a primary function of the uPA-
uPAR couple is to focus the processing of the plasminogen
zymogen to active plasmin on the cell surface. It has
recently been demonstrated that binding of u-PA to its
receptor increases pro-MMP-2,-9 [23] and -13 [16] activa-
tion, and that in the absence of cells, plasmin not only
fails to activate pro-MMPs, but rapidly degrades them
[23]. This would explain why interfering with only one
element, plasmin or MMP activity, has such powerful bio-
logical effects. It should be stressed, however, that few of
the cascades or activities have been unequivocally docu-
mented in intact cell systems. Nonetheless, because MMP-
specific inhibitors are not yet available, the individual role
of each of the cell-derived MMPs awaits the use of inter-
ventions based on RNA inhibition.
The increased bone resorption that accompanies breast
cancer cell infiltration of bone may arise as a result of (1)
breast cancer cells stimulating osteoblast and osteoclast
activity and (2) the production by breast cancer cells of
proteinases that participate in degrading the organic
aspect of bone matrix which would also facilitate the
access of osteoclasts to the underlying mineralized matrix.
Even if tumour-derived MMPs do not directly digest min-
eralized matrix, they may participate in osteolysis via a
mechanism that is analogous to a known osteoblast
function. It is believed that all endosteal surfaces are cov-
ered with a layer of nonmineralized matrix. In areas of
bone formation, this layer is called osteoid and it is easily
observed in stained sections [24]. Evidence is accumulat-
ing that degradation of this layer must occur before the
attachment of osteoclasts to the underlying mineralized
matrix [25]. In normal remodelling, digestion of this layer
is apparently accomplished by MMPs produced by oste-
oblasts [25-27]. It is conceivable that breast cancer cells in
bone adopt this osteoblast function; thus, the possibility
that MMPs produced by cancer cells enhance osteoclastic
degradation by prior removal of the overlying unmineral-
ized layer. Furthermore, removal of this layer may be par-
tially responsible for the recruitment and activity of
osteoclasts due to the release of osteoclast attractants/
stimulants. Bone resorption by osteoclasts is augmented
experimentally by coating mineralized matrix with colla-
genase-cleaved collagen fragments [28]. As nonmineral-
ized matrix is degraded, osteoclasts may be exposed to
extracellular proteins, such as fibronectin, vitronectin,
osteopontin or other cryptic epitopes. Osteoclasts bind to
these proteins via integrins a process that may enhance
bone resorption [29].
Conclusion
In conclusion, we have shown that breast cancer cells can
degrade the organic aspect of bone matrix in contrast to
non-tumourogenic breast epithelial cells. There is an
absolute requirement for both the PA system and MMPs
in the degradation process.
Materials and methods
Reagents
The MMP inhibitor CT-1166 was a generous gift from Dr
A Docherty, Celltech (Slough, UK). The PAS inhibitor
aprotinin, plasminogen and TGFβ were purchased from
Sigma. The human mammary epithelial cell (HMEC) line,
Mammary Epithelial Basal Medium (MEBM), insulin,
hydrocortisone, gentamicin/amphotericin-B and Bovine
Pituitary Extract (BPE) were purchased from Clonetics
(Walkersville, MD, USA). Human breast tumour cell lines
MDA-231, ZR-75-1 and MCF-7 were purchased from
ATCC (American Type Culture Collection, Manassas, VA,
USA). Gelatinase-A, TIMP-1 and polyclonal sheep anti-
bodies to human MMP-1, -2,- 3, -9 and -13 were gifts from
Dr J Reynolds, Strangeways Research Laboratory, Cam-
bridge, UK. Neutralizing mAbs against human uPA or
human uPAR were from American Diagnostica, Green-
wich, CT, USA.
Cell cultures
Cell lines were cultured in 75-cm2 plastic tissue culture
flasks (Costar Corning, Cambridge, MA, USA) as follows:
ZR-75-1, MDA-231, MCF-7 and MC-3T3-E1 in α-MEM
and HME cells in MEBM medium. All media were supple-
mented with 10% heat inactivated fetal bovine serum
(FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100
ug/ml streptomycin (Sigma Chemical Co.). Cultures were
maintained at 37°C in a humidified atmosphere of 95%
air and 5% carbon dioxide and subcultured every third
day.
Type I collagen degradation assay
14C-labelled collagen films were prepared as described
previously [30]. Breast cells were seeded into collagen
coated 16 mm tissue culture wells at a density of 1 × 105 /
well. After 4 h incubation at 37°C in MEM supplemented
with 10% FCS, the cells were washed twice with phos-
phate buffered saline (PBS) to remove residual FCS, and
incubated for 24 h with 1 ml/well of serum-free MEM
with or without the indicated concentrations of plasmino-Cancer Cell International 2005, 5:1 http://www.cancerci.com/content/5/1/1
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gen, TGFβ and the proteinase inhibitors to be tested. At
the end of the culture period the media were centrifuged
(15 min, 1200 × g) to remove any collagen fibrils, and
radioactivity released during collagen degradation quanti-
fied by liquid scintillation counting. Residual collagen
was digested with bacterial collagenase (50 µg/ml) and
assayed for radioactivity. Collagenolysis was expressed as
radioactivity released from the films as a percentage of the
total ± SEM.
Formation of 3H-labelled, non-mineralized and 
mineralized bone matrix
The murine calvarial-derived MC3T3-E1 is a well charac-
terized osteoblast culture system providing a suitable
model of osteogenesis analogous to in vivo bone
formation [15]. The cultures were maintained at 37°C in
a humidified atmosphere of 95% air and 5% carbon diox-
ide. Culture medium was changed on the first day after
seeding and then every 72 h. The cells were split after 7–9
days in culture, before they reached confluence, and
plated at a density of 1 × 104 cells/well on collagen-coated
24-well plates (Becton Dickinson, MA, USA). After 4–5
days, when the cultures had reached confluence and the
formation of an ECM had started, fresh medium was
added containing 1 µCi/ml 3H amino acid mixture for 7
days (Amersham International, Aylesbury, UK) to create a
non-mineralized radiolabelled ECM. In order to create a
mineralized bone matrix, the medium was supplemented
with 10 mM β-glycerol phosphate and the cells cultured
for 14 days and the radiolabelled medium changed every
3 days. Unincorporated 3H-radiolabelled amino acids
were washed from the remaining ECM using 2 water
washes and 75% (v/v) ethanol. The matrices were dried
and stored at -20°C until use.
Von Kossa staining for mineralization
Mineralization of matrices was determined by von Kossa
staining. The matrices were rinsed with cold PBS and fixed
in 10% neutral buffered formalin for 15 min, rinsed with
distilled water and left in distilled water for 15 min.
Matrices were stained with 2.5 % silver nitrate solution for
30 min at room temperature. The silver nitrate was
removed and matrices were rinsed with distilled water
before the addition of sodium carbonate formaldehyde
for 5 min. After rinsing, the matrices were counterstained
with toluidine blue, rinsed with tap water and air dried.
Bone matrix degradation assay
Breast cancer cells (105 /16 mm culture well) were seeded
onto the bone matrix as for the type I collagen degrada-
tion assay. After 4 h incubation at 37°C in MEM supple-
mented with 10% FCS, the cells were washed twice with
phosphate buffered saline (PBS) to remove residual FCS,
and incubated for 24 h with 1 ml/well of serum-free MEM
with or without the indicated concentrations of plasmino-
gen, TGFβ and the proteinase inhibitors that were tested.
After 24 h incubation, the media were removed and the
extent of degraded 3H-radiolabelled matrix released into
the medium was determined by liquid scintillation count-
ing. The remaining matrix was degraded as for the type I
collagen assay and matrix degradation expressed as above.
PCR and RT-PCR
Confluent breast tumour cells were stimulated with TGFβ
(10-10 M) in serum-free medium for 24 h. For PCR analy-
sis, oligonucleotide primers were synthesized based on
the published sequences for 14 MMPs (i.e., MMP-1, -2, -3,
-7,-8,-9,-10, -11, -12, -13,-14,-15, -16, and -17) [4]. t-PA,
u-PA and, u-PAR oligonucleotides were designed using
Designer PCR (Research Genetics, AL, USA) and primers
purchased from Life Technologies Ltd. The housekeeping
gene GAPDH was used as a positive control for the RT-
PCR methodology.
Enzymes and buffers for the reverse transcriptase and PCR
reactions were obtained from Perkin Elmer (CA, USA).
Reverse transcriptase reactions were done according to the
manufacturer's protocol using 1 µg of total RNA collected
from untreated or TGF-β treated breast cells. PCR reac-
tions were performed in an automated DNA thermal
cycler (Perkin Elmer) for 25 cycles of denaturation (95°C,
1 min), annealing (variable time and temperature) and
polymerisation (60°C, variable time). Amplification of
the house-keeping gene, G3PDH mRNA (35 cycles), pro-
vided an internal control for the efficiency of the RT-PCR
process. RT-PCR products were analyzed against molecu-
lar weight standards (pBR322 HaeIII digest) on a 2.5%
agarose gel stained with ethidium bromide, electro-
phoresed in 0.5× TBE buffer at 100 V for 90 minutes. Gels
were examined under ultraviolet light and photographed.
The authenticity of the PCR products was verified by
sequencing [31].
Western Blot analysis
To identify MMP proteins and uPA present in breast cell
conditioned medium, Western blot analysis was per-
formed using their specific antibodies as previously
described [32]. Briefly, samples were separated by 8.5%
SDS-PAGE, transblotted on to PVDF membranes (Milli-
pore Corp., MA, USA) and immunoblotted with polyclo-
nal sheep antiserum to MMPs or polyclonal goat
antiserum to uPA and secondary peroxidase-conjugated
anti-sheep / anti-goat antibodies. Labelled proteins were
detected with ECL detection solution and exposed to
autoradiographic film (Hyperfilm ECL, Amersham Inter-
national, UK).
Assay of collagenase activity
To measure collagenase activity, TGFβ (10-10 M)-stimu-
lated breast cells were cultured in the presence/absence ofCancer Cell International 2005, 5:1 http://www.cancerci.com/content/5/1/1
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2 ug/ml of human plasminogen for 24 h. Collagenase
activity was measured by the degradation of fluorescein
isothiocyanate (FITC)-labelled type I collagen using type I
activity assay kits. One unit of these activities degrades 1
µg of collagen per min at 37°C.
uPA Assay
Cells were plated in 6-well trays and grown to near conflu-
ence, the medium was removed, and the cells were
washed and incubated with 2 ml of serum-free medium
for 24 hr. The medium was collected, centrifuged, and fro-
zen until assayed. The cells were lysed in 300 ul of 0.1 M
Tris (pH 8.1) and 0.1% Triton X-100. The u-PA (10 ul of
conditioned medium and 10 µg of cell protein) was
assayed as previously described [41] using plasminogen
and S2251, the chromogenic substrate for plasmin.
Statistical Analysis
Differences between control and treatment groups were
determined by the Mann Whitney U-test.
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